Holen Sie sich die Stockscreener-App
4.45
3.49%
0.15
Handel nachbörslich:
4.51
0.06
+1.35%
Schlusskurs vom Vortag:
$4.30
Offen:
$4.35
24-Stunden-Volumen:
33,739
Relative Volume:
0.75
Marktkapitalisierung:
$33.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-101.87M
KGV:
-3.156
EPS:
-1.41
Netto-Cashflow:
$-83.46M
1W Leistung:
-3.68%
1M Leistung:
-1.55%
6M Leistung:
-30.47%
1J Leistung:
-29.74%
1-Tages-Spanne:
$4.35
$4.556
1-Wochen-Bereich:
$4.06
$4.67
52-Wochen-Spanne:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
Firmenname
Kezar Life Sciences Inc
Sektor
Branche
Telefon
650-822-5600
Adresse
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie KZR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.45 | 33.75M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Wells Fargo | Outperform |
| 2018-07-16 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kezar Life Sciences Inc Aktie (KZR) Neueste Nachrichten
Is Kezar Life Sciences Inc. a good long term investmentUnprecedented profits - jammulinksnews.com
What drives Kezar Life Sciences Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
Kezar Life Sciences Inc. Stock Analysis and ForecastAccelerated capital growth - jammulinksnews.com
When (KZR) Moves Investors should Listen - news.stocktradersdaily.com
Kezar Life Sciences’ (KZR) Neutral Rating Reiterated at HC Wainwright - Defense World
What analysts say about Kezar Life Sciences Inc. stockTremendous gains - jammulinksnews.com
How high can Kezar Life Sciences Inc. stock price go in 2025Chart Based Entries - Newser
HC Wainwright & Co. Maintains Neutral Rating on Kezar Life Sciences - AInvest
In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial - insights.citeline.com
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study - Benzinga
FDA lifts partial hold on Kezar’s zetomipzomib trial - The Pharma Letter
KZR: Kezar Life Sciences Maintains Neutral Rating by HC Wainwrig - GuruFocus
Kezar Says US FDA Lifts Partial Clinical Hold on Zetomipzomib Trial in Autoimmune Hepatitis; Shares Rise After Hours - MarketScreener
Kezar Life Sciences stock gains after FDA lifts partial clinical hold - Investing.com Canada
Organon & Co. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your RightsOGN - The Globe and Mail
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire
What makes Kezar Life Sciences Inc. stock price move sharplyProven Trading Plan - Newser
Why Kezar Life Sciences Inc. stock attracts strong analyst attentionFree Predictions - Newser
How BPYPP stock performs during market volatilityExpert Trading Flow - Newser
How Kezar Life Sciences Inc. stock performs during market volatilityStrong Return Daily Alerts - Newser
Consensus Cloud Secures $225 Million Credit Facility - The Globe and Mail
How Li Bang International Corporation Inc. stock performs during market volatilitySwing Trade Signals - Newser
Where Will ARK 21Shares Bitcoin ETF Be in 5 Years? - The Globe and Mail
Bragg Gaming Expands U.S. Presence with Fanatics Casino Launch - The Globe and Mail
Where are the Opportunities in (KZR) - news.stocktradersdaily.com
SemiLEDs Reports Third Quarter Fiscal Year 2025 Financial Results - The Globe and Mail
Kezar Life Sciences (NASDAQ:KZR) Shares Up 2% – Time to Buy? - Defense World
(KZR) Proactive Strategies - news.stocktradersdaily.com
Kezar Life Sciences, Inc.(NasdaqCM: KZR) added to Russell Microcap Value Index - MarketScreener
Kezar Shareholders Re-Elect Board, Approve Pay Package in 2025 Vote | KZR SEC FilingForm 8-K - Stock Titan
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Cuts Holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
(KZR) On The My Stocks Page - news.stocktradersdaily.com
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - The Manila Times
Northern Trust Corp Reduces Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference 2025 - BioSpace
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - The Joplin Globe
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Kezar Life Sciences Reports Positive Trial Results - TipRanks
Finanzdaten der Kezar Life Sciences Inc-Aktie (KZR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):